Novel molecular targets for urothelial carcinoma

Expert Opinion on Therapeutic Targets

Volumn 19, Issue 4, 2015, Pages 515-525

  Faltas, Bishoy M ^a   Karir, Beerinder S ^a   Tagawa, Scott T ^a   Rosenberg, Jonathan E ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Genomics; molecular targets; targeted therapy; urothelial carcinoma

Indexed keywords

3 (2,6 DICHLORO 3,5 DIMETHOXYPHENYL) 1 [6 [[4 (4 ETHYL 1 PIPERAZINYL)PHENYL]AMINO] 4 PYRIMIDINYL] 1 METHYLUREA; 3,3',4',5 TETRAHYDROXY 6,7 DIMETHOXYFLAVONE; 5 AZA 2' DEOXYCYTIDINE; APATORSEN; BUPARLISIB; CETUXIMAB; CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOVITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GEFITINIB; HEAT SHOCK PROTEIN 27; IPILIMUMAB; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MPDL 3280A; OMIPALISIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TRASTUZUMAB; TUBERIN; VORINOSTAT; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CHROMATIN ASSEMBLY AND DISASSEMBLY; DRUG TARGETING; ENZYME ACTIVE SITE; GENE MUTATION; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN PHOSPHORYLATION; REVIEW; TRANSITIONAL CELL CARCINOMA; ANIMAL; CARCINOMA, TRANSITIONAL CELL; DRUG APPROVAL; DRUG DESIGN; DRUG RESISTANCE; FOOD AND DRUG ADMINISTRATION; MOLECULARLY TARGETED THERAPY; PATHOLOGY; UNITED STATES; UROTHELIUM;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; DRUG APPROVAL; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; UROTHELIUM;

EID: 84924912373     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.987662     Document Type: Review

References (108)

1. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003;4(4):257-62
2. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008;27(41):5497-510
3. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455(7216):1061-8
4. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474(7353):609-15
5. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499(7456):43-9
6. The Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497(7447):67-73
7. Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014;505(7484):495-501
8. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507(7492):315-22
9. Iyer G, Al-Ahmadie H, Schultz N, et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol 2013;31(25):3133-40
10. PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha [Homo sapiens (human)] - Gene - NCBI [Internet]. Available from: http://www.ncbi.nlm.nih.gov/gene?cmd=Retrieve&dopt=full-report&list-uids=5290
11. Platt FM, Hurst CD, Taylor CF, et al. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res 2009;15(19):6008-17
12. Ross RL, Askham JM, Knowles MA. PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs. Oncogene 2013;32(6):768-76
13. López-Knowles E, Hernández S, Malats N, et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 2006;66(15):7401-4
14. Dueñas M, Martínez-Fernández M, García-Escudero R, et al. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors. Mol Carcinog 2013. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24347284. [Epub ahead of print]
15. Sjödahl G, Lauss M, Gudjonsson S, et al. A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. PLoS ONE 2011;6(4):e18583
16. Buparlisib in metastatic transitional cell carcinoma of the urothelium - full text view. ClinicalTrials.gov [Internet]. Available from: http://clinicaltrials.gov/show/NCT01551030
17. PI3K kinase inhibitor GSK2126458 (GSK458): clinical activity in select patient (pt) populations defined by predictive markers (study P3K112826) [Internet]. Available from: http://abstracts.webges.com/viewing/view.php?congress=esmo2012&congress-id=370&publication-id=1500
18. Tsuruta H, Kishimoto H, Sasaki T, et al. Hyperplasia and carcinomas in Ptendeficient mice and reduced PTEN protein in human bladder cancer patients. Cancer Res 2006;66(17):8389-96
19. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 2009;23(6):675-80
20. Platt FM, Hurst CD, Taylor CF, et al. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res 2009;15(19):6008-17
21. Loss of PTEN leads to clinical resistance to the PI3Kα inhibitor BYL719 and provides evidence of convergent evolution under selective therapeutic pressure [Internet]. Available from: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=1ec08f7b-2c2b-44b4-a03a-5fea49231668&cKey=6af1cb5f-9156-4d86-bf0c-2c45c9ae0324&mKey={6FFE1446-A164-476A-92E7-C26446874D93>}
22. Calderaro J, Rebouissou S, de Koning L, et al. PI3K/AKT pathway activation in bladder carcinogenesis. Int J Cancer 2013;3:1776-84
23. Askham JM, Platt F, Chambers PA, et al. AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K. Oncogene 2010;29(1):150-5
24. Ross JS, Wang K, Al-Rohil RN, et al. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. Mod Pathol 2014;27(2):271-80
25. Guo Y, Chekaluk Y, Zhang J, et al. TSC1 involvement in bladder cancer: diverse effects and therapeutic implications. J Pathol 2013;230(1):17-27
26. Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012;338(6104):221
27. Gomez-Pinillos A, Ferrari AC. mTOR signaling pathway and mTOR inhibitors in cancer therapy. Hematol Oncol Clin North Am 2012;26(3):483-505
28. Milowsky MI, Iyer G, Regazzi AM, et al. Phase II study of everolimus in metastatic urothelial cancer. BJU Int 2013;112(4):462-70
29. Seront E, Rottey S, Sautois B, et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol 2012;23(10):2663-70
30. Seront E, Pinto A, Bouzin C, et al. PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation. Br J Cancer 2013;109(6):1586-92
31. Wagle N, Grabiner BC, Van Allen EM, et al. Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib. Cancer Discov 2014;4(5):546-53
32. The Cancer Genome Atlas Research Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490(7418):61-70
33. Laé M, Couturier J, Oudard S, et al. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol 2010;21(4):815-19
34. Krüger S, Weitsch G, Büttner H, et al. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer 2002;102(5):514-18
35. Latif Z, Watters AD, Dunn I, et al. HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer 2003;89(7):1305-9
36. Ross JS, Wang K, Al-Rohil RN, et al. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. Mod Pathol 2014;27(2):271-80
37. Grivas PD, Day M, Hussain M. Urothelial carcinomas: a focus on human epidermal receptors signaling. Am J Transl Res 2011;3(4):362-73
38. Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 2007;25(16):2218-24
39. Beuzeboc P, Banu E, Voog E, et al. Trastuzumab (T) combined with standard chemotherapy in HER+ metastatic bladder cancer (BC) patients: Interim safety results of a prospective randomized phase II study ASCO Meeting Abstracts [Internet]. J Clin Oncol 2007.25(18 Suppl):15565. Available from: http://meeting.ascopubs.org/cgi/content/abstract/25/18-suppl/15565
40. DN24-02 as adjuvant therapy in subjects with high risk HER2+ urothelial carcinoma - full text view. ClinicalTrials. gov [Internet]. Available from: http://clinicaltrials.gov/show/NCT01353222
41. Preliminary safety, product parameters, and immune response assessments from a phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy (ACI), in patients (pts) with surgically resected HER2+ urothelial cancer (UC) at high ri [Internet]. Available from: http://meetinglibrary.asco.org/content/114690-132
42. A double blind randomised study of lapatinib and placebo in metastatic TCC of the urothelium - full text view. ClinicalTrials.gov [Internet]. Available from: http://clinicaltrials.gov/show/NCT00949455
43. Ross JS, Wang K, Gay LM, et al. A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma. Clin Cancer Res 2014;20(1):68-75
44. Ali SM, Alpaugh RK, Downing SR, et al. Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy. J Clin Oncol 2014;32(25):e88-91
45. An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification - full text view. ClinicalTrials.gov [Internet]. Available from: http://clinicaltrials.gov/ct2/show/NCT01953926
46. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366(1):2-16
47. Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell 2000;100:57-70
48. Fiorentino M, Giunchi F, Altimari A, et al. Learning from errors: response to gefitinib in kidney urothelial carcinoma with EGFR mutations. Oncologist 2014;19(4):430
49. Petrylak DP, Tangen CM, Van Veldhuizen PJ, et al. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int 2010;105(3):317-21
50. Wong Y-N, Litwin S, Vaughn D, et al. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol 2012;30(28):3545-51
51. Philips GK, Halabi S, Sanford BL, et al. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol 2009;20(6):1074-9
52. HDAC inhibitors reverse epithelial-to-mesenchymal transition (EMT) and restore sensitivity to EGFR inhibitors in urothelial carcinoma cells. Available from: http://meetinglibrary.asco.org/content/20366-64
53. Iyer G, Milowsky MI. Fibroblast growth factor receptor-3 in urothelial tumorigenesis. Urol Oncol 2013;31(3):303-11
54. Billerey C, Chopin D, Bralet M, et al. Frequent FGFR3 mutations in pappilary non-invasive bladder (pTa) tumors. Am J Pathol 2001;158(6):1955-9
55. Van Rhijn BW, van der Kwast TH, Liu L, et al. The FGFR3 mutation is related to favorable pT1 bladder cancer. J Urol 2012;187(1):310-14
56. Iyer G, Al-Ahmadie H, Schultz N, et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol 2013;31(25):3133-40
57. Williams S V, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet 2013;22(4):795-803
58. Di Martino E, Tomlinson DC, Knowles MA. A decade of FGF receptor research in bladder cancer: past, present, and future challenges. Adv Urol 2012;2012:429213
59. Lamont FR, Tomlinson DC, Cooper PA, et al. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer 2011;104(1):75-82
60. Dovitinib in BCG refractory urothelial carcinoma with FGFR3 mutations or over-expression - full text view. ClinicalTrials.gov [Internet]. Available from: http://clinicaltrials.gov/show/NCT01732107
61. Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3. J Clin Oncol 2013.31(Suppl 6):abstract 255. Available from: http://meetinglibrary.asco.org/content/106458-134
62. Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors [Internet]. Available from: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3404&sKey=a56e6bb6-7ce7-4f58-89a7-f118d4efb710&cKey=25b2209a-5959-45f1-a777-4414cb7cdf21&mKey=6ffe1446-a164-476a-92e7-c26446874d93
63. First in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors [Internet]. Available from: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3404&sKey=a56e6bb6-7ce7-4f58-89a7-f118d4efb710&cKey=ad57afb0-3d24-44fc-8ee8-ae21e404d85a&mKey=6ffe1446-a164-476a-92e7-c26446874d93
64. Garraway LA, Jänne PA. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov 2012;2(3):214-26
65. Herrera-Abreu MT, Pearson A, Campbell J, et al. Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. Cancer Discov 2013;3(9):1058-71
66. A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC). J Clin Oncol 2014.32(Suppl 4):abstract 307. Available from: http://meetinglibrary.asco.org/content/124412-142
67. Kamada M, So A, Muramaki M, et al. Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol Cancer Ther 2007;6(1):299-308
68. A phase 2 study comparing chemotherapy in combination with OGX-427 or placebo in patients with bladder cancer - full text view. ClinicalTrials.gov [Internet]. Available from: http://clinicaltrials.gov/show/NCT01454089
69. Phase 2 study of docetaxel +/- OGX-427 in patients with relapsed or refractory metastatic bladder cancer - full text view. ClinicalTrials.gov [Internet]. Available from: http://clinicaltrials.gov/show/NCT01780545
70. Garg M, Kanojia D, Seth A, et al. Heat-shock protein 70-2 (HSP70-2) expression in bladder urothelial carcinoma is associated with tumour progression and promotes migration and invasion. Eur J Cancer 2010;46(1):207-15
71. Vignali M, Hassan AH, Neely KE, Workman JL. ATP-dependent chromatin-remodeling complexes. Mol Cell Biol 2000;20(6):1899-910
72. Gui Y, Guo G, Huang Y, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 2011;43(9):875-8
73. Decitabine in treating patients with advanced solid tumors - full text view. ClinicalTrials.gov [Internet]. Available from: http://clinicaltrials.gov/ct2/show/NCT00030615
74. Niegisch G, Knievel J, Koch A, et al. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. Urol Oncol 2013;31(8):1770-9
75. Kelly WK, Richon VM, O'Connor O, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003;9(10 Pt 1):3578-88
76. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23(17):3923-31
77. Phase II study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced transitional cell urothelial cancer (TCC) after platinum-based therapy - California Cancer Consortium/University of Pittsburgh NCI/CTEP-sponsored trial - Cheung [Internet]. Available from: http://meeting.ascopubs.org/cgi/content/abstract/26/15-suppl/16058
78. Rosik L, Niegisch G, Fischer U, et al. Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells. Cancer Biol Ther 2014;15(6):742-57
79. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5):646-74
80. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013;342(6165):1432-3
81. OncLive. Investigational immunotherapy granted first breakthrough therapy designation in bladder cancer [Internet]. 2014. Available from: http://www.onclive.com/conference-coverage/asco-2014/Investigational-Immunotherapy-Granted-First-Breakthrough-Therapy-Designation-in-Bladder-Cancer
82. Bladder cancer treatment (PDQ®). National Cancer Institute [Internet]. Available from: http://www.cancer.gov/cancertopics/pdq/treatment/bladder/HealthProfessional/page1/AllPages#Section-323
83. Lamm D, Brausi M, O'Donnell MA, Witjes JA. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer. Urol Oncol 2014;32(1):35.e21-30
84. Carthon BC, Wolchok JD, Yuan J, et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 2010;16(10):2861-71
85. First-line gemcitabine, cisplatin + ipilimumab for metastatic urothelial carcinoma - full text view. ClinicalTrials.gov [Internet]. Available from: http://clinicaltrials.gov/show/NCT01524991
86. Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). J Clin Oncol 2014.32:(Suppl):abstract 5011. Available from: http://abstracts.asco.org/144/AbstView-144-128960.html
87. A Study of MPDL3280A in patients with locally advanced or metastatic urothelial bladder cancer - full text view. ClinicalTrials.gov [Internet] Available from: http://clinicaltrials.gov/ct2/show/NCT02108652?term=anti+PD1+urothelial&rank=1
88. Oral lenalidomide and intravesical BCG for therapy of bladder cancer - full text view. ClinicalTrials.gov [Internet] Available from: http://clinicaltrials.gov/show/NCT01373294
89. Zamble DB, Lippard SJ. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 1995;20(10):435-9
90. Konstantakou EG, Voutsinas GE, Karkoulis PK. Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses. Int J Oncol 2009;35:401-16
91. Walker MC, Povey S, Parrington JM, et al. Development and characterization of cisplatin-resistant human testicular and bladder tumour cell lines. Eur J Cancer 1990;26(6):742-7
92. Drayton RM, Catto J. Molecular mechanisms of cisplatin resistance in bladder cancer. Expert Rev Anticancer Ther 2012;12(2):271-81
93. Sandlow J, Cohen MB, Robinson RA, et al. DNA ploidy and P-glycoprotein expression as predictive factors of response to neoadjuvant chemotherapy for invasive bladder cancer. Urology 1994;43(6):787-91
94. Bahnson RR, Becich M, Ernstoff MS, et al. Absence of immunohistochemical metallothionein staining in bladder tumor specimens predicts response to neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy. J Urol 1994;152(6 Pt 2):2272-5
95. Kimiya K, Naito S, Soejima T, et al. Establishment and characterization of doxorubicin-resistant human bladder cancer cell line, KK47/ADM. J Urol 1992;148(2 Pt 1):441-5
96. Kim WJ, Kakehi Y, Hirai M, et al. Multidrug resistance-associated protein-mediated multidrug resistance modulated by cyclosporin A in a human bladder cancer cell line. Jpn J Cancer Res 1995;86(10):969-77
97. Clifford SC, Neal DE, Lunec J. Alterations in expression of the multidrug resistance-associated protein (MRP) gene in high-grade transitional cell carcinoma of the bladder. Br J Cancer 1996;73(5):659-66
98. Taniguchi K, Wada M, Kohno K, Kawakami M. Cancer cell lines with decreased drug accumulation ahuman canalicular multispecific organic anion transporter (cMOAT). Gene Cancer Res 1996;56:4124-9
99. Tada YT, Wada MW, Igita TM, et al. Increasd expression of Multidrug Resisitance-Associated Proteins in bladder cancer during clinical course and drug resistance to Doxorubicin. Int J Cancer 2002;635:630-5
100. Masters JR, Thomas R, Ha AG, et al. Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxiwg pathways. Eur J Cancer 1996;32A(7):1248-53
101. Xu BH, Gupta V, Singh S V. Characterization of a human bladder cancer cell line selected for resistance to mitomycin C. Int J Cancer 1994;58(5):686-92
102. Yokomizo A, Ono M, Nanri H, Mitomycin C. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide advances in brief cellular levels of thioredoxin associated with drug sensitivity to cisplatin. Cancer Res 1995;55(19):4293-6
103. Van Allen EM, Mouw KW, Kim P, et al. Somatic ERCC2 Mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 2014;4(10):1140-53
104. Clinical study of microdosing carboplatin in lung or bladder cancer - tabular view. ClinicalTrials.gov [Internet]. Available from: http://clinicaltrials.gov/ct2/show/record/NCT01261299
105. Cho HJ, Kim JK, Kim KD, et al. Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. Cancer Lett 2006;237(1):56-66
106. Bolenz C, Becker A, Trojan L, et al. Optimizing chemotherapy for transitional cell carcinoma by application of bcl-2 and bcl-xL antisense oligodeoxynucleotides. Urol Oncol 2007;25(6):476-82
107. Miyake H, Hanada N, Nakamura H, et al. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer. Oncogene 1998;16(7):933-43
108. Yoon CY, Park MJ, Lee JS, et al. The histone deacetylase inhibitor trichostatin A synergistically resensitizes a cisplatin resistant human bladder cancer cell line. J Urol 2011;185(3):1102-11